Ilika plc (AIM:IKA)

Regulus Therapeutics Income Statement

Financials in millions GBP. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Operating Revenue	0.07	0.02	0.03	0.03	0.23
Other Revenue	0.98	2.07	0.67	0.47	2.03
Revenue	1.05	2.09	0.7	0.5	2.26
Revenue Growth (YoY)	-49.64%	197.81%	41.50%	-78.01%	-20.59%
Cost of Revenue	0.53	1.08	0.4	0.22	1.27
Gross Profit	0.53	1.01	0.3	0.28	0.98
Selling, General & Admin	8.09	7.78	9.37	8.4	4.83
Other Operating Expenses	-	-0.53	-0.08	-	-
Operating Expenses	8.09	7.25	9.3	8.4	4.83
Operating Income	-7.56	-6.24	-9	-8.12	-3.84
Interest Expense	-0.05	-0.03	-0.04	-0.03	-0.01
Interest & Investment Income	0.39	0.51	0.11	0.01	0.01
Other Non Operating Income (Expenses)	-	-	-0	-	-
Pretax Income	-7.22	-5.77	-8.93	-8.14	-3.84
Income Tax Expense	-1.31	-0.95	-1.63	-1.02	-0.31
Net Income	-5.9	-4.81	-7.3	-7.13	-3.53
Net Income to Common	-5.9	-4.81	-7.3	-7.13	-3.53
Shares Outstanding (Basic)	159	159	158	153	139
Shares Outstanding (Diluted)	159	159	158	153	139
Shares Change (YoY)	-	0.40%	3.41%	9.98%	33.09%
EPS (Basic)	-0.04	-0.03	-0.05	-0.05	-0.03
EPS (Diluted)	-0.04	-0.03	-0.05	-0.05	-0.03
Free Cash Flow	-5.25	-3.31	-6.53	-9.14	-3.96
Free Cash Flow Per Share	-0.03	-0.02	-0.04	-0.06	-0.03
Gross Margin	50.02%	48.25%	42.45%	55.90%	43.63%
Operating Margin	-718.10%	-298.47%	-1281.69%	-1636.59%	-170.29%
Profit Margin	-560.57%	-230.24%	-1039.32%	-1436.91%	-156.36%
Free Cash Flow Margin	-498.36%	-158.19%	-929.99%	-1842.30%	-175.38%
EBITDA	-6.02	-4.91	-7.7	-7.09	-2.79
EBITDA Margin	-	-235.09%	-	-	-123.53%
D&A For EBITDA	1.54	1.32	1.29	1.02	1.05
EBIT	-7.56	-6.24	-9	-8.12	-3.84
EBIT Margin	-	-298.47%	-	-	-170.29%
Revenue as Reported	1.05	2.09	0.7	0.5	2.26

Updated Jan 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.